UA57001U - Method for prediction of risk of thrombolitic complications in patients with anti-phospholipid syndrome - Google Patents

Method for prediction of risk of thrombolitic complications in patients with anti-phospholipid syndrome

Info

Publication number
UA57001U
UA57001U UAU201006873U UAU201006873U UA57001U UA 57001 U UA57001 U UA 57001U UA U201006873 U UAU201006873 U UA U201006873U UA U201006873 U UAU201006873 U UA U201006873U UA 57001 U UA57001 U UA 57001U
Authority
UA
Ukraine
Prior art keywords
risk
prediction
patients
complications
thrombolitic
Prior art date
Application number
UAU201006873U
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Сергей Викторович Шевчук
Любовь Викторовна Присяжнюк
Галина Викторовна Бессмертная
Юлия Сергеевна Сегеда
Original Assignee
Научно-Исследовательский Институт Реабилитации Инвалидов (Учебно-Научный Лечебный Комплекс) Винницкого Национального Медицинского Университета Им. H.И. Пирогова
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Научно-Исследовательский Институт Реабилитации Инвалидов (Учебно-Научный Лечебный Комплекс) Винницкого Национального Медицинского Университета Им. H.И. Пирогова filed Critical Научно-Исследовательский Институт Реабилитации Инвалидов (Учебно-Научный Лечебный Комплекс) Винницкого Национального Медицинского Университета Им. H.И. Пирогова
Priority to UAU201006873U priority Critical patent/UA57001U/en
Publication of UA57001U publication Critical patent/UA57001U/en

Links

Abstract

Method for prediction of risk of thrombotic complications in patients with anti-phospholipid syndrome includes determination of aggregation of thombocytes, thrombocytopenia, activation of PAI-1, protein C and S, activity of bera-2-glicoprotein 1, activity of pro-inflammation cytokines IL-1, IL-6, FNP-alpha. At increase of levels of the last ones one predicts risk of thrombosis.
UAU201006873U 2010-06-03 2010-06-03 Method for prediction of risk of thrombolitic complications in patients with anti-phospholipid syndrome UA57001U (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
UAU201006873U UA57001U (en) 2010-06-03 2010-06-03 Method for prediction of risk of thrombolitic complications in patients with anti-phospholipid syndrome

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
UAU201006873U UA57001U (en) 2010-06-03 2010-06-03 Method for prediction of risk of thrombolitic complications in patients with anti-phospholipid syndrome

Publications (1)

Publication Number Publication Date
UA57001U true UA57001U (en) 2011-02-10

Family

ID=50830439

Family Applications (1)

Application Number Title Priority Date Filing Date
UAU201006873U UA57001U (en) 2010-06-03 2010-06-03 Method for prediction of risk of thrombolitic complications in patients with anti-phospholipid syndrome

Country Status (1)

Country Link
UA (1) UA57001U (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11143659B2 (en) 2015-01-27 2021-10-12 Arterez, Inc. Biomarkers of vascular disease

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11143659B2 (en) 2015-01-27 2021-10-12 Arterez, Inc. Biomarkers of vascular disease
US11821905B2 (en) 2015-01-27 2023-11-21 Arterez, Inc. Biomarkers of vascular disease

Similar Documents

Publication Publication Date Title
PH12017501417A1 (en) Anti-fap antibodies and methods of use
CY1124698T1 (en) IL-18 BINDING PROTEIN (IL-18BP) IN INFLAMMATORY DISEASES
MX355256B (en) Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof.
PH12015501656A1 (en) Anti-il-33 antibodies and use thereof
PH12016500331A1 (en) Survival benefit in patients with solid tumors with elevated c-reactive protein levels
WO2011154139A3 (en) Gene expression markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment
MX348013B (en) Anti-il-17f antibodies and methods of use thereof.
CR20120371A (en) PCSK9 ANTAGONISTS
EP2542581A4 (en) Antibody specific for apolipoprotein and methods of use thereof
EA201301180A1 (en) BCMA-BASED STRATIFICATION AND THERAPY OF PATIENTS SUFFERING WITH MULTIPLE MYELOMA
MX355268B (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF.
EA201491388A1 (en) RECOMBINANT PROTEINS OF FACTOR VIII
PA8847001A1 (en) HIGH AFFINITY HUMAN ANTIBODIES FOR THE IL-4-HUMAN RECEIVER
MX370348B (en) Targeted modified il-1 family members.
UA114277C2 (en) Anti-angiogenesis therfpy for the treatment of ovarian cancer
UA113609C2 (en) ANTIGENCY BINDING PROTEIN Binding HUMAN IL-23
GB2488091A (en) Humanized anti-interleukin 3 receptor alpha chain antibodies
PH12015502102B1 (en) Reducing proinflammatory response
WO2009135861A3 (en) Humanized antibodies against human interferon-alpha
NZ629828A (en) Methods for the treatment of b cell-mediated inflammatory diseases
UA109148C2 (en) Compositions based on anti-vegfr-3 antibody
UA57001U (en) Method for prediction of risk of thrombolitic complications in patients with anti-phospholipid syndrome
MX2015015232A (en) Monoclonal antibody directed against cxcr5.
GB201103780D0 (en) Treatment for ige-mediated disease
UA60581U (en) method for predicting the risk of thrombotic complications in fracture